Biotechnology News and Research

RSS

Senate Finance Committee's bipartisan bill is the best blueprint for comprehensive health care reform: PhRMA

"Today's vote represents an important step forward for the millions of Americans who don't have access to high-quality and affordable health care coverage and services. Chairman Baucus has tirelessly shepherded one of the most important pieces of legislation in our lifetime and deserves a lot of credit for reaching out to members on both sides of the aisle.

14 Oct 2009

Fraunhofer CSE opens new PV module laboratory

This afternoon, Fraunhofer USA, Inc.'s Center for Sustainable Energy Systems (CSE) officially opened its first laboratory, a PV module innovation facility at a high-profile ribbon-cutting ceremony headlined by German Ambassador Klaus Scharioth and Massachusetts Energy Secretary Bowles.

14 Oct 2009

VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").

14 Oct 2009

International Stem Cell launches human cell culture products into commercial research markets

International Stem Cell Corporation, announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs.

14 Oct 2009

Research reveals the genetic basis of DispersinB enzyme substrate based biofilm formation in bacteria

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse bacterial biofilms is pleased to announce that a recent research publication from Princeton University reveals the genetic basis of poly-ß-1,6-N-acetylglucosamine (PNAG), the DispersinB® enzyme substrate, based biofilm formation in bacteria.

14 Oct 2009

FDA recommends approval for UI Pharmaceuticals to manufacture an aseptically filled sterile drug product

In September 2009, the Kansas City District Office of the Food and Drug Administration (FDA) submitted a recommendation of approval to the Center for Drug Evaluation and Research for The University of Iowa Pharmaceuticals (UIP) to manufacture and test an aseptically filled, sterile prescription drug product for a commercial client. The drug product contains a new chemical entity and is a sterile solution that is aseptically filled into vials.

14 Oct 2009

New generation of forensic DNA kits to provide faster DNA results

Applied Biosystems, part of Life Technologies Corporation, today announced a new generation of forensic DNA kits with chemistry reagents designed to address the increasing challenges facing 21st century forensic laboratories.

14 Oct 2009

Sosei Group assigns its SD281 drug discovery programme to Biocopea

Sosei Group Corporation, a biopharmaceutical company, today announces the assignment of the drug discovery programme, SD281 and its analogues, to Biocopea Limited, a UK biotechnology company and subsidiary of PepTcell Limited. These compounds, based on a metabolite of a well-known drug, were shown by Sosei to have pronounced anti-inflammatory properties.

14 Oct 2009

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

Champions Biotechnology, Inc., a drug development company with a preclinical platform able to predict clinical effectiveness, accelerate development and enhance the value of oncology drugs, today announced that the United States Patent and Trademark Office issued a patent on September 29, 2009 for the company's tubulin inhibitors, including its lead compound SG410.

14 Oct 2009

NIH awards Novavax a SBIR grant for respiratory syncytial virus vaccine research

Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.

14 Oct 2009

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Metabolic Solutions Development Company (MSDC) announced today that it has received a $100,000 grant from the Alzheimer's Drug Discovery Foundation (ADDF) to support the evaluation of PPAR-sparing insulin sensitizers as a potential treatment for Alzheimer's disease.

14 Oct 2009

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

BioMimetic Therapeutics, Inc. today announced positive top-line results from its North American pivotal (Phase III) randomized controlled trial comparing its fully synthetic, off-the-shelf bone growth factor product, Augment Bone Graft (“Augment”), to autograft for use in hindfoot and ankle fusion surgery.

14 Oct 2009

Positive results from Alkermes' ALKS 33 clinical trials announced

Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.

13 Oct 2009

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Dyax Corp. announced today new developments involving drug candidates identified using the Company’s proprietary phage display technology as a result of two deals recently announced by sanofi-aventis.

13 Oct 2009

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Compugen Ltd. announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany covering the further evaluation of a Compugen discovered tumor target and its splice variants.

13 Oct 2009

Talecris Biotherapeutics Holdings to raise $550 million through private placement

Talecris Biotherapeutics Holdings Corp. today announced that it has commenced an offering through a private placement of $550 million aggregate principal amount of senior notes due 2016 (the “Notes”). Talecris intends to use the proceeds from the offering to repay its First and Second Lien Term Loans, repay a portion of borrowings under its Revolving Credit Facility, and to pay related fees and expenses.

13 Oct 2009

Exhibitors display latest biotechnology products and applications at BIOTECHNICA 2009

Chalking up an increase in the number of exhibitors and trade visitors plus the amount of display space sold, the BIOTECHNICA, exhibition (6 to 8 October 2009) sent some important signals in the midst of an economic crisis.

13 Oct 2009

PharmaNet Development to display innovative solutions at 2009 AAPS Annual Meeting and Exposition

PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the Company and its subsidiaries Anapharm and Taylor Technology will be showcasing a range of innovative solutions at the 2009 AAPS Annual Meeting and Exposition.

13 Oct 2009

SAFC Pharma expands contract manufacturing services

SAFC Pharma®, a business segment of SAFC®, a member of the Sigma-Aldrich® Group, today announced the completion of an addition to its Carlsbad, Calif., facility that expands the Company's contract manufacturing services for its late phase and commercial clients.

13 Oct 2009

$SAFC Pharma's Pharmorphix Solid State Research Laboratories installs new single crystal X-ray diffraction system$

SAFC Pharma's Pharmorphix Solid State Research Laboratories installs new single crystal X-ray diffraction system

SAFC Pharma®, a business segment of SAFC®, a member of the Sigma-Aldrich® Group, today announced that its Pharmorphix® Solid State Research Laboratories in Cambridge, UK, have installed a new single crystal X-ray diffraction system. The Oxford Diffraction SuperNova(TM) system, which can determine the crystal structures from the most challenging crystal samples, is the first industrial installation of this state-of-the-art instrumentation anywhere in the world.

13 Oct 2009

Biotechnology News and Research

Senate Finance Committee's bipartisan bill is the best blueprint for comprehensive health care reform: PhRMA

Fraunhofer CSE opens new PV module laboratory

VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market

International Stem Cell launches human cell culture products into commercial research markets

Research reveals the genetic basis of DispersinB enzyme substrate based biofilm formation in bacteria

FDA recommends approval for UI Pharmaceuticals to manufacture an aseptically filled sterile drug product

New generation of forensic DNA kits to provide faster DNA results

Sosei Group assigns its SD281 drug discovery programme to Biocopea

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

NIH awards Novavax a SBIR grant for respiratory syncytial virus vaccine research

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

Positive results from Alkermes' ALKS 33 clinical trials announced

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Talecris Biotherapeutics Holdings to raise $550 million through private placement

Exhibitors display latest biotechnology products and applications at BIOTECHNICA 2009

PharmaNet Development to display innovative solutions at 2009 AAPS Annual Meeting and Exposition

SAFC Pharma expands contract manufacturing services

SAFC Pharma's Pharmorphix Solid State Research Laboratories installs new single crystal X-ray diffraction system

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News